Form 4: Pacific Biosciences Director William Ericson Granted 65,000 Stock Options

Pacific Biosciences of California, Inc. director William W. Ericson was granted 65,000 stock options with an exercise price of $1.03, vesting monthly over one year.

Summary

• William W. Ericson, a Director of Pacific Biosciences of California, Inc. (PACB), was granted 65,000 stock options.
• The options have an exercise price of $1.03 per share.
• The grant date for these options was June 4, 2025.
• The options will begin to vest on July 4, 2025, and will vest monthly over a one-year period.
• Full vesting is contingent upon Mr. Ericson's continued service as a director through the applicable vesting dates.
• The options have an expiration date of June 4, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns the director's interests with shareholder value and serves as a retention incentive. While it implies future dilution upon exercise, it's a standard compensation practice.

Positives

• The grant of stock options to Director William W. Ericson aligns his interests with those of shareholders, incentivizing long-term performance and retention.
• The options have a long expiration date (June 4, 2035), providing a significant window for potential value realization.

Negatives

• The grant of 65,000 stock options, once exercised, will result in a minor dilution of existing shareholder equity.

Risks

• The vesting of the stock options is contingent on William W. Ericson's continued service as a director, meaning the options could be forfeited if his service ceases before full vesting.
• The value of the options is dependent on the future stock price of Pacific Biosciences of California, Inc. exceeding the exercise price of $1.03.

Future Outlook

NA

Industry Context

This is a routine insider compensation event for a director in a publicly traded biotechnology or genomics company. Such grants are common practice to attract and retain qualified board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across many industries, including biotechnology and life sciences, for companies like Illumina, Twist Bioscience, or Oxford Nanopore Technologies, which also utilize equity incentives to align director interests with shareholder value.
• The one-year monthly vesting schedule is a common approach for director equity grants, aiming to ensure continued engagement and service.

Corporate Governance

Related Party Transactions

• The grant of 65,000 stock options to William W. Ericson, a director of Pacific Biosciences of California, Inc., constitutes a related party transaction as it involves an equity award from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon exercise of the options, but also improved alignment of director interests with long-term shareholder value.

Next Steps

• The stock options will vest monthly over one year, contingent on William W. Ericson's continued service as a director.

Key Dates

Keywords

Pacific Biosciences, PACB, stock options, insider transaction, Form 4, director compensation, equity grant, beneficial ownership, William Ericson